Guggenheim analyst Seamus Fernandez downgrades Icosavax (NASDAQ:ICVX) from Buy to Neutral.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2023 | $28.00 | Buy | Guggenheim |
| 1/4/2023 | $27.00 | Outperform | Oppenheimer |
| 6/29/2022 | $18.00 | In-line → Outperform | Evercore ISI |
| 3/25/2022 | $50.00 → $10.00 | Outperform → In-line | Evercore ISI |
| 12/29/2021 | $50.00 | Buy | Jefferies |
| 8/23/2021 | $50.00 | Outperform | Evercore ISI Group |
| 8/23/2021 | $45.70 | Outperform | William Blair |
| 8/23/2021 | Outperform | Cowen & Co. |
Simpson has helped build 11 companies that have been acquired or gone public, most recently serving as CEO of Icosavax Frazier Life Sciences (FLS), a longstanding investment firm investing in innovative biopharmaceuticals, today announced the addition of industry veteran Adam Simpson as Venture Partner in its Company Creation team. Over the last 25 years, Simpson has served as a co-founder, executive and/or board member of 11 life sciences companies that have either been acquired or gone public. His broad experience from these roles focuses on team building, advancing novel technologies through clinical proof-of-concept and leading significant fundraising, partnerships and acquisitions. H
PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics ("CHARM", "The Company"), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine. The newly formed Board is comprised of world-leading experts whose skillsets span 3D deep learning and protein structure prediction, drug discovery and oncology. These individuals have a deep understanding of CHARM and
Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ:ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX
Guggenheim initiated coverage of Icosavax with a rating of Buy and set a new price target of $28.00
Oppenheimer initiated coverage of Icosavax with a rating of Outperform and set a new price target of $27.00
Evercore ISI upgraded Icosavax from In-line to Outperform and set a new price target of $18.00
SC 13D/A - Icosavax, Inc. (0001786255) (Subject)
SC 13D/A - Icosavax, Inc. (0001786255) (Subject)
SC 13G/A - Icosavax, Inc. (0001786255) (Subject)
15-12G - Icosavax, Inc. (0001786255) (Filer)
SC TO-T/A - Icosavax, Inc. (0001786255) (Subject)
EFFECT - Icosavax, Inc. (0001786255) (Filer)
Guggenheim analyst Seamus Fernandez downgrades Icosavax (NASDAQ:ICVX) from Buy to Neutral.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday. The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&P 500 also rose, gaining, 0.26% to 4,634.47. Check This Out: Microsoft, U.S. Bancorp And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Materials shares rose by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.7%. Top Headline Johnson Controls International plc (NYSE:JCI) reported weak results for its fourth quarter. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the c
Shares of Johnson Controls International plc (NYSE:JCI) moved lower during Tuesday’s session following weak quarterly results. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the consensus of $7.09 billion. Adjusted EPS of $1.05 (+6% Y/Y) below the consensus of $1.09, according to Benzinga Pro. Johnson Controls International shares fell 6.2% to $53.05 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Aditxt, Inc. (NASDAQ:ADTX) shares jumped 140.5% to $9.14 after the company entered into definitive agreement to acquire Evofem Biosciences. C4 Therapeutics, Inc. (NASDAQ:CCCC) gai
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: Exercised option for patent license for influenza vaccine from the University of Washington (UW) and U.S. Department of Human and Health Services (HHS). Icosavax has exercised its option for a non-exclusive patent license granted by UW and HHS for use of its computationally designed, two component VLP platform in the influenza field, as the company executes on its strategy to
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research and development, including at two of the most prominent vaccine companies in the world, Sanofi Pasteur and Merck & Co., Inc. He has guided scientific teams to create novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including RSV, infl
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel. "Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies," said Adam Simpson, Chief Executive Officer of Icosavax. "I am thrilled to begin working alongside Elizabeth and look forward to her valuable insight as we work to progress our clinical candidates down the development pipeline and continue to grow the compa
- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform technology - - Icosavax plans to file an IND submission and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + hMPV VLP candidate, in 2H 2022 – - Company to host conference call/webcast today at 4:30 p.m. ET / 1:30 p.m. PT - SEATTLE, June 28, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP